1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Precision Cancer Diagnostic Tests Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Imaging
1.2.3 Molecular
1.2.4 Histology/Cytology
1.2.5 Tumor Marker Immunoassays
1.2.6 POC Colon Cancer Tests
1.3 Market by Application
1.3.1 Global Precision Cancer Diagnostic Tests Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Precision Cancer Diagnostic Tests Market Perspective (2018-2032)
2.2 Precision Cancer Diagnostic Tests Growth Trends by Region
2.2.1 Precision Cancer Diagnostic Tests Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Precision Cancer Diagnostic Tests Historic Market Size by Region (2018-2023)
2.2.3 Precision Cancer Diagnostic Tests Forecasted Market Size by Region (2023-2032)
2.3 Precision Cancer Diagnostic Tests Market Dynamics
2.3.1 Precision Cancer Diagnostic Tests Industry Trends
2.3.2 Precision Cancer Diagnostic Tests Market Drivers
2.3.3 Precision Cancer Diagnostic Tests Market Challenges
2.3.4 Precision Cancer Diagnostic Tests Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Precision Cancer Diagnostic Tests Players by Revenue
3.1.1 Global Top Precision Cancer Diagnostic Tests Players by Revenue (2018-2023)
3.1.2 Global Precision Cancer Diagnostic Tests Revenue Market Share by Players (2018-2023)
3.2 Global Precision Cancer Diagnostic Tests Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Precision Cancer Diagnostic Tests Revenue
3.4 Global Precision Cancer Diagnostic Tests Market Concentration Ratio
3.4.1 Global Precision Cancer Diagnostic Tests Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Precision Cancer Diagnostic Tests Revenue in 2022
3.5 Precision Cancer Diagnostic Tests Key Players Head office and Area Served
3.6 Key Players Precision Cancer Diagnostic Tests Product Solution and Service
3.7 Date of Enter into Precision Cancer Diagnostic Tests Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Precision Cancer Diagnostic Tests Breakdown Data by Type
4.1 Global Precision Cancer Diagnostic Tests Historic Market Size by Type (2018-2023)
4.2 Global Precision Cancer Diagnostic Tests Forecasted Market Size by Type (2023-2032)
5 Precision Cancer Diagnostic Tests Breakdown Data by Application
5.1 Global Precision Cancer Diagnostic Tests Historic Market Size by Application (2018-2023)
5.2 Global Precision Cancer Diagnostic Tests Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Precision Cancer Diagnostic Tests Market Size (2018-2032)
6.2 North America Precision Cancer Diagnostic Tests Market Size by Country (2018-2023)
6.3 North America Precision Cancer Diagnostic Tests Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Precision Cancer Diagnostic Tests Market Size (2018-2032)
7.2 Europe Precision Cancer Diagnostic Tests Market Size by Country (2018-2023)
7.3 Europe Precision Cancer Diagnostic Tests Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Precision Cancer Diagnostic Tests Market Size (2018-2032)
8.2 Asia-Pacific Precision Cancer Diagnostic Tests Market Size by Country (2018-2023)
8.3 Asia-Pacific Precision Cancer Diagnostic Tests Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Precision Cancer Diagnostic Tests Market Size (2018-2032)
9.2 Latin America Precision Cancer Diagnostic Tests Market Size by Country (2018-2023)
9.3 Latin America Precision Cancer Diagnostic Tests Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Precision Cancer Diagnostic Tests Market Size (2018-2032)
10.2 Middle East & Africa Precision Cancer Diagnostic Tests Market Size by Country (2018-2023)
10.3 Middle East & Africa Precision Cancer Diagnostic Tests Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Precision Cancer Diagnostic Tests Introduction
11.1.4 Abbott Laboratories Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Detail
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Precision Cancer Diagnostic Tests Introduction
11.2.4 Agilent Technologies Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.2.5 Agilent Technologies Recent Development
11.3 Becton Dickinson and Company
11.3.1 Becton Dickinson and Company Company Detail
11.3.2 Becton Dickinson and Company Business Overview
11.3.3 Becton Dickinson and Company Precision Cancer Diagnostic Tests Introduction
11.3.4 Becton Dickinson and Company Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.3.5 Becton Dickinson and Company Recent Development
11.4 Bio-Rad Laboratories
11.4.1 Bio-Rad Laboratories Company Detail
11.4.2 Bio-Rad Laboratories Business Overview
11.4.3 Bio-Rad Laboratories Precision Cancer Diagnostic Tests Introduction
11.4.4 Bio-Rad Laboratories Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.4.5 Bio-Rad Laboratories Recent Development
11.5 Biocartis N.V.
11.5.1 Biocartis N.V. Company Detail
11.5.2 Biocartis N.V. Business Overview
11.5.3 Biocartis N.V. Precision Cancer Diagnostic Tests Introduction
11.5.4 Biocartis N.V. Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.5.5 Biocartis N.V. Recent Development
11.6 Biocept
11.6.1 Biocept Company Detail
11.6.2 Biocept Business Overview
11.6.3 Biocept Precision Cancer Diagnostic Tests Introduction
11.6.4 Biocept Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.6.5 Biocept Recent Development
11.7 bioMerieux SA
11.7.1 bioMerieux SA Company Detail
11.7.2 bioMerieux SA Business Overview
11.7.3 bioMerieux SA Precision Cancer Diagnostic Tests Introduction
11.7.4 bioMerieux SA Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.7.5 bioMerieux SA Recent Development
11.8 Canon Medical Systems Corporation
11.8.1 Canon Medical Systems Corporation Company Detail
11.8.2 Canon Medical Systems Corporation Business Overview
11.8.3 Canon Medical Systems Corporation Precision Cancer Diagnostic Tests Introduction
11.8.4 Canon Medical Systems Corporation Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.8.5 Canon Medical Systems Corporation Recent Development
11.9 Cynvenio Biosystems
11.9.1 Cynvenio Biosystems Company Detail
11.9.2 Cynvenio Biosystems Business Overview
11.9.3 Cynvenio Biosystems Precision Cancer Diagnostic Tests Introduction
11.9.4 Cynvenio Biosystems Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.9.5 Cynvenio Biosystems Recent Development
11.10 Danaher Corporation
11.10.1 Danaher Corporation Company Detail
11.10.2 Danaher Corporation Business Overview
11.10.3 Danaher Corporation Precision Cancer Diagnostic Tests Introduction
11.10.4 Danaher Corporation Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.10.5 Danaher Corporation Recent Development
11.11 Epigenomics AG
11.11.1 Epigenomics AG Company Detail
11.11.2 Epigenomics AG Business Overview
11.11.3 Epigenomics AG Precision Cancer Diagnostic Tests Introduction
11.11.4 Epigenomics AG Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.11.5 Epigenomics AG Recent Development
11.12 Exosome Diagnostics
11.12.1 Exosome Diagnostics Company Detail
11.12.2 Exosome Diagnostics Business Overview
11.12.3 Exosome Diagnostics Precision Cancer Diagnostic Tests Introduction
11.12.4 Exosome Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.12.5 Exosome Diagnostics Recent Development
11.13 Foundation Medicine
11.13.1 Foundation Medicine Company Detail
11.13.2 Foundation Medicine Business Overview
11.13.3 Foundation Medicine Precision Cancer Diagnostic Tests Introduction
11.13.4 Foundation Medicine Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.13.5 Foundation Medicine Recent Development
11.14 General Electric Company
11.14.1 General Electric Company Company Detail
11.14.2 General Electric Company Business Overview
11.14.3 General Electric Company Precision Cancer Diagnostic Tests Introduction
11.14.4 General Electric Company Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.14.5 General Electric Company Recent Development
11.15 Genomic Health
11.15.1 Genomic Health Company Detail
11.15.2 Genomic Health Business Overview
11.15.3 Genomic Health Precision Cancer Diagnostic Tests Introduction
11.15.4 Genomic Health Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.15.5 Genomic Health Recent Development
11.16 Hologic
11.16.1 Hologic Company Detail
11.16.2 Hologic Business Overview
11.16.3 Hologic Precision Cancer Diagnostic Tests Introduction
11.16.4 Hologic Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.16.5 Hologic Recent Development
11.17 Illumina
11.17.1 Illumina Company Detail
11.17.2 Illumina Business Overview
11.17.3 Illumina Precision Cancer Diagnostic Tests Introduction
11.17.4 Illumina Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.17.5 Illumina Recent Development
11.18 Menarini Silicon Biosystems SpA
11.18.1 Menarini Silicon Biosystems SpA Company Detail
11.18.2 Menarini Silicon Biosystems SpA Business Overview
11.18.3 Menarini Silicon Biosystems SpA Precision Cancer Diagnostic Tests Introduction
11.18.4 Menarini Silicon Biosystems SpA Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.18.5 Menarini Silicon Biosystems SpA Recent Development
11.19 Myriad Genetics
11.19.1 Myriad Genetics Company Detail
11.19.2 Myriad Genetics Business Overview
11.19.3 Myriad Genetics Precision Cancer Diagnostic Tests Introduction
11.19.4 Myriad Genetics Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.19.5 Myriad Genetics Recent Development
11.20 NanoString Technologies
11.20.1 NanoString Technologies Company Detail
11.20.2 NanoString Technologies Business Overview
11.20.3 NanoString Technologies Precision Cancer Diagnostic Tests Introduction
11.20.4 NanoString Technologies Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.20.5 NanoString Technologies Recent Development
11.21 Ortho Clinical Diagnostics
11.21.1 Ortho Clinical Diagnostics Company Detail
11.21.2 Ortho Clinical Diagnostics Business Overview
11.21.3 Ortho Clinical Diagnostics Precision Cancer Diagnostic Tests Introduction
11.21.4 Ortho Clinical Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.21.5 Ortho Clinical Diagnostics Recent Development
11.22 QIAGEN N.V.
11.22.1 QIAGEN N.V. Company Detail
11.22.2 QIAGEN N.V. Business Overview
11.22.3 QIAGEN N.V. Precision Cancer Diagnostic Tests Introduction
11.22.4 QIAGEN N.V. Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.22.5 QIAGEN N.V. Recent Development
11.23 Randox Laboratories Ltd.
11.23.1 Randox Laboratories Ltd. Company Detail
11.23.2 Randox Laboratories Ltd. Business Overview
11.23.3 Randox Laboratories Ltd. Precision Cancer Diagnostic Tests Introduction
11.23.4 Randox Laboratories Ltd. Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.23.5 Randox Laboratories Ltd. Recent Development
11.24 Roche Holding AG
11.24.1 Roche Holding AG Company Detail
11.24.2 Roche Holding AG Business Overview
11.24.3 Roche Holding AG Precision Cancer Diagnostic Tests Introduction
11.24.4 Roche Holding AG Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.24.5 Roche Holding AG Recent Development
11.25 Royal Philips N.V.
11.25.1 Royal Philips N.V. Company Detail
11.25.2 Royal Philips N.V. Business Overview
11.25.3 Royal Philips N.V. Precision Cancer Diagnostic Tests Introduction
11.25.4 Royal Philips N.V. Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.25.5 Royal Philips N.V. Recent Development
11.26 Siemens AG
11.26.1 Siemens AG Company Detail
11.26.2 Siemens AG Business Overview
11.26.3 Siemens AG Precision Cancer Diagnostic Tests Introduction
11.26.4 Siemens AG Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.26.5 Siemens AG Recent Development
11.27 Thermo Fisher Scientific
11.27.1 Thermo Fisher Scientific Company Detail
11.27.2 Thermo Fisher Scientific Business Overview
11.27.3 Thermo Fisher Scientific Precision Cancer Diagnostic Tests Introduction
11.27.4 Thermo Fisher Scientific Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.27.5 Thermo Fisher Scientific Recent Development
11.28 Vela Diagnostics
11.28.1 Vela Diagnostics Company Detail
11.28.2 Vela Diagnostics Business Overview
11.28.3 Vela Diagnostics Precision Cancer Diagnostic Tests Introduction
11.28.4 Vela Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2018-2023)
11.28.5 Vela Diagnostics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
